AORT three-lens brief
Evidence-based stock research on AORT. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -2.26% yesterday. · 50-day MA below 200-day MA (death-cross regime); price below both.
- Moved -2.26% yesterday.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 14.4pp over 30 days.
- P/E of 106 — priced for high growth; little margin of safety.
- Analyst mean target $42.15 — 71% above current (8 analysts).
AORT closed at $24.65 (-2.26%) as of 2026-09-11. Market cap: $1.20B. P/E (trailing) 106.2. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $42.15 — 71% above current (8 analysts).. Concerns: moved -2.26% yesterday.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $125.76M, net income -$13.51M, free cash flow $13.10M.
Why three lenses on AORT, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AORTacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AORT" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AORT brief"></iframe>